Darius Moshfeghi, MD
Retina Specialist · Palo Alto, CANPI 1386702819
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,387,973 of the $1,449,188 with a category attached, or 95.8%. 15 manufacturers reported payments, led by AstraZeneca at 49.8% of the total. 2025 is the largest year on record at $372,743, 4.9 times the $75,959 reported in 2019. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $10,979 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$721K
- Ocular Therapeutix, Inc.$566K
- Bayer$87K
- Regeneron$63K
- Boehringer Ingelheim International GmbH$4K
- Alcon$4K
- plus $5K from 9 others
Across 36 payments — averaging $6567.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$189K
- Apellis Pharmaceuticals, Inc.$42K
- Regeneron$5K
- F. Hoffmann-la Roche AG$281
What the payments were for
- Consulting fees$1,387,97396%
- Travel & lodging$57,0364%
- Food & beverage$4,1600%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $721,034 |
| Ocular Therapeutix, Inc. | 53 | $565,802 |
| Bayer | 9 | $86,814 |
| Regeneron | 13 | $62,554 |
| Boehringer Ingelheim International GmbH | 2 | $4,250 |
| Alcon | 7 | $3,764 |
| Akebia Therapeutics Inc | 1 | $3,000 |
| Genentech, Inc. | 1 | $1,515 |
| Apellis Pharmaceuticals, Inc. | 2 | $86 |
| Topcon Healthcare, Inc. | 1 | $84 |
| Eyepoint US, Inc. | 1 | $81 |
| Novartis | 1 | $77 |
| AbbVie | 1 | $66 |
| Astellas Pharma US Inc | 1 | $42 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$86,814
- EYLEA$62,444
- Constellation$2,947
- DEXTENZA$2,527
How this compares
$1,449,188 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 13 | $541 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Palo Alto
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
- Diana DoStanford$318K
- Sahar BedroodPasadena$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.